Law & Regulation
Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center
The study is an attempt to revive ancient healing practices using natural medicines among the Māori people.
The post Canada’s Optimi Health to ship…
Canadian psychedelics company Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) inked a deal to supply a New Zealand research institute with psilocybin, giving the company a boost to its international dealings.
Although Optimi already has a psychedelic footprint in neighboring Australia, the new supply deal – with the Mātai Medical Research Institute on behalf of the Tū Wairua Project – is the first such agreement for Optimi with any entity in New Zealand.
Optimi’s British Columbia-made psilocybin extracts will be utilized by a clinical study focused on native Maori tribal members dealing with methamphetamine use disorder.
“This agreement marks our entry into a new market and underscores the historical and cultural importance of the work being undertaken by our colleagues in New Zealand to honour and respect the indigenous heritage of the Māori people,” Optimi CEO Bill Ciprick said in a press release.
The company did not disclose financial terms of the deal or the amount of psilocybin to be supplied, but it will provide the institute with “a quantity of its validated GMP Full Spectrum Natural Psilocybin extract,” following news a week ago that three of its psilocybin batches had undergone full release testing and obtained certificates of analysis, a key hurdle in proving product quality.
The study is an attempt by the New Zealand tribe to revive ancient healing and cultural practices using natural medicines, Jody Toroa, trustee of Rangiwaho Marae, added in the release.
“Alongside many First Nations peoples, we have a relationship with native flora and fauna as a source of healing and reconnection to our respective indigenous cultural practices,” Toroa said. “Optimi medicines provide the closest natural fungi to the marae’s local, indigenous species, which for Rangiwaho Marae and the Tū Wairua collective, is key to the integrity of the project. Synthetic products, by comparison, are not conducive to our reclaiming of cultural knowledge and customary practice.”
Optimi also won permission last fall to supply a Canadian government-run health program with psilocybin and MDMA.
The post Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center appeared first on Green Market Report.
research psychedelics psychedelic psilocybin mdma-
Law & Regulation6 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psilocybin1 week ago
The Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic